How Lipid Droplets and Mitochondria Talk — and Why It Matters for Metabolic Disease
A 2025 review reveals how lipid droplet–mitochondria crosstalk drives diabetes, fatty liver, and obesity at the molecular level.
Summary
Lipid droplets (LDs) and mitochondria communicate through specialized membrane contact sites (MCSs) to regulate fat storage, mobilization, and oxidation. This 2025 review synthesizes how two interaction modes — dynamic 'kiss-and-run' contact and stable anchoring — are orchestrated by key proteins including PLIN5, Mfn2, SNAP23, and VPS13 family members. When these interactions break down, fatty acid overload, excess reactive oxygen species (ROS), and mitochondrial dysfunction ensue, fueling metabolic diseases such as type 2 diabetes, metabolic dysfunction-associated fatty liver disease (MAFLD), and obesity. The authors argue that targeting specific proteins at LD–mitochondria interfaces represents a promising therapeutic frontier.
Detailed Summary
Metabolic diseases — including type 2 diabetes, obesity, and metabolic dysfunction-associated fatty liver disease (MAFLD) — share a common cellular thread: dysregulated lipid handling and mitochondrial dysfunction. This comprehensive 2025 review from Chinese researchers synthesizes emerging evidence that lipid droplets (LDs) and mitochondria are not merely co-located organelles but active partners in metabolic regulation, communicating via membrane contact sites (MCSs) positioned just 10–30 nm apart.
The review delineates two mechanistically distinct interaction modes. Dynamic contact, following a 'kiss-and-run' model, enables rapid, reversible FA exchange. Key mediators include SNAP23 (a SNARE protein recruited to LDs during fasting), PLIN5 (which recruits mitochondria to LDs via its C-terminal domain and activates lipolysis through ATGL/ABHD5 under AMPK signaling), and ACSL1 (which forms a molecular platform with SNAP23/VAMP4 for FA channeling). Stable anchoring, by contrast, involves long-duration transmembrane complexes — notably PLIN5–FATP4 and Mfn2–Hsc70 pairings — that ensure continuous lipid supply in high-energy tissues like heart and brown adipose tissue. Importantly, these two modes share regulatory proteins and can interconvert in response to metabolic state changes.
The ER plays an indispensable intermediary role, with proteins such as VPS13D, MIGA2, and Rab18 facilitating three-way LD–ER–mitochondria crosstalk. MIGA2, a mitochondrial outer membrane protein, tethers LDs to mitochondria while simultaneously promoting lipogenesis; Rab18 recruits the NRZ tethering complex and SNARE machinery to LD–ER–mitochondria interfaces. These multi-organelle hubs coordinate lipid synthesis, storage, and oxidation in an integrated network.
Dysregulation of LD–mitochondria interactions (LDMC) initiates a pathogenic cascade central to metabolic disease. In diabetes, impaired PLIN5 and Mfn2 function disrupts FA channeling, causing lipotoxic ROS accumulation that damages pancreatic β-cells and skeletal muscle insulin signaling. In MAFLD, excessive LD accumulation in hepatocytes coincides with mitochondrial structural and functional deterioration, impairing β-oxidation and accelerating steatosis and fibrosis. In obesity, hypertrophied adipocyte LDs overwhelm mitochondrial oxidative capacity, perpetuating a cycle of lipotoxicity and inflammation.
The review highlights several specific proteins — PLIN5, Mfn2, SNAP23, VPS13D, MIGA2, and Rab18 — as compelling therapeutic targets, as modulating them could restore LD–mitochondria coupling and metabolic homeostasis. However, tissue-specific expression patterns, incomplete interactome maps, and the complexity of three-organelle networks remain significant knowledge gaps. The authors call for advanced imaging and proteomics approaches to fully resolve MCS architecture and dynamics across tissues and disease states.
Key Findings
- PLIN5 mediates both dynamic and stable LD–mitochondria contact, regulating FA transport and PPARα transcription under energy stress.
- SNAP23 is recruited to LDs during fasting and forms complexes with ACSL1/VAMP4 to facilitate FA channeling to mitochondria.
- Mfn2 forms tissue-specific complexes (with Hsc70 in heart, PLIN1 in brown fat) to couple LDs to mitochondria and sustain β-oxidation.
- Dysregulated LD–mitochondria interactions drive ROS overproduction, lipotoxicity, and organelle dysfunction in diabetes, MAFLD, and obesity.
- VPS13D and MIGA2 mediate ER–LD–mitochondria three-way contacts critical for lipid transport and metabolic coordination.
Methodology
This is a narrative review synthesizing published molecular biology, cell biology, and disease-model studies on LD–mitochondria interactions. No primary experimental data were generated; evidence is drawn from in vitro cell studies, animal models, and human tissue observations. The authors provide a systematic framework organizing findings by interaction mode (dynamic vs. stable) and disease context.
Study Limitations
As a narrative review, it does not include meta-analytic synthesis or risk-of-bias assessment of primary studies. Many mechanistic insights derive from animal models or cell lines, with limited direct human tissue validation. Tissue-specific roles of key proteins (e.g., PLIN5, Mfn2) and the complete molecular architecture of LD–ER–mitochondria three-way contacts remain incompletely characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: